

Review

Not peer-reviewed version

---

# Ventilator-Associated Lung Injury: Pathophysiology, Prevention, and Emerging Therapeutic Strategies

---

[Ana Costa](#) , [Bintia Sakho](#) , Sangel Gomez , [Brandon Khanyan](#) , [Pamella Leybengrub](#) , [Sergio Bergese](#) \*

Posted Date: 22 September 2025

doi: 10.20944/preprints202509.1656.v1

Keywords: lung injury; ventilator associated lung injury; ventilator induced lung injury; personalized medicine; acute respiratory distress syndrome; mechanical ventilation



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

# Ventilator-Associated Lung Injury: Pathophysiology, Prevention, and Emerging Therapeutic Strategies

Ana Costa <sup>1</sup>, Bintia Sakho <sup>1</sup>, Sangel Gomez <sup>1</sup>, Brandon Khanyan <sup>2</sup>, Pamela Leybengrub <sup>2</sup> and Sergio Bergese <sup>1,\*</sup>

<sup>1</sup> Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA

<sup>2</sup> Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA

\* Correspondence: sergio.bergese@stonybrookmedicine.edu

## Abstract

Mechanical ventilation is a critical intervention in patients that cannot spontaneously maintain adequate oxygenation and remove carbon dioxide. However, it can also lead to severe lung injury via volutrauma, barotrauma, atelectrauma and biotrauma, and it can worsen existing lung disease such as acute respiratory distress syndrome. Ventilator-associated lung injury, the clinical manifestations of lung damage associated with mechanical ventilation, can trigger systemic inflammatory cascades that contribute to multi-organ failure. The utilization of lung-protective ventilation strategies helps to minimize further injury to the lungs during mechanical ventilation and improve survival rates. This review discusses the pathophysiology of ventilator-associated lung injury, including cellular and molecular responses, its systemic effects, risk factors, clinical presentation and diagnosis, protective strategies, and emerging therapies.

**Keywords:** lung injury; ventilator associated lung injury; ventilator induced lung injury; personalized medicine; acute respiratory distress syndrome; mechanical ventilation

## 1. Introduction

Mechanical ventilation is a lifesaving intervention when spontaneous ventilation is compromised such as in trauma, neuromuscular weakness, sepsis, respiratory failure, etc. It provides a mechanism for oxygenation and carbon dioxide removal. However, mechanical ventilation can cause lung injury via volutrauma, barotrauma, atelectrauma and biotrauma, and it can exacerbate conditions like acute respiratory distress syndrome (ARDS) as well as increase morbidity and mortality in intensive-care patients. Thus, in patients where mechanical ventilation is a life-saving intervention, lung protective ventilation strategies must be utilized to minimize harm.

Ventilator-associated lung injury (VALI) refers to the clinical manifestations of lung damage associated with mechanical ventilation [1]. Ventilator-induced lung injury (VILI) refers to the actual biological damage to the lung caused directly by mechanical ventilation. VILI is often morphologically and physiologically indistinguishable from VALI, it can only be discerned definitively in animal models [2]. VILI is sometimes used as a synonym for VALI, however VILI is a term better applied to a patient with VALI where mechanical ventilation is the proven cause of the lung injury. On the other hand, VALI is a broader term utilized when the cause of lung injury has not been determined and may have been caused by mechanical ventilation or worsening of underlying lung conditions while on mechanical ventilation.

The exact incidence of VALI is difficult to determine since it overlaps with ARDS and other causes of lung injury and it is difficult to establish causation of lung injury by mechanical ventilation alone. Gajic *et al.* found that 24% of the 332 mechanically ventilated patients without acute lung injury at the onset developed new lung injury by day 5 [3]. The LUNG SAFE study found that 10.4% of

intensive care unit (ICU) admissions and up to 23% of mechanically ventilated patients met criteria for ARDS, and VALI may contribute to or worsen the condition [4]. In a cohort of 1113 mechanically ventilated patients, Rubenfeld *et al.* found the incidence of acute lung injury was 78.9 cases per 100,000 person-years, the incidence of ARDS was 58.7% cases per 100,000 person-years, and the in-hospital mortality rate for patients with acute lung injury was 38.5% whereas the mortality rate for patient with ARDS was 41.1% [5].

Since mechanical ventilation is a life-saving measure but can also cause severe injury, it is critical to understand VALI in order to optimize mechanical ventilation settings and minimize further injury to critically ill patients. Furthermore, VALI can trigger systemic inflammatory cascades that contribute to multi-organ failure [6]. The ARDSNet Low Tidal Volume Trial demonstrated significantly lower mortality with lower tidal volumes in ARDS ventilated patients compared to traditional tidal volume ventilation (31% vs 39.8%) [7]. Thus, preventing VALI via lung-protective ventilation contributes to better survival rates and decreased length of ICU stays. This review discusses the pathophysiology of VALI, including cellular and molecular responses, its systemic effects, risk factors, clinical presentation and diagnosis, protective strategies, and emerging therapies (Figure 1).




Figure 1. Graphic abstract. @ [Sery Pak] via Canva.com.

## 2. Pathophysiology of Ventilator-Associated Lung Injury

### 2.1. Mechanisms of Injury

VALI occurs when the forces from mechanical ventilation are greater than what the lung tissue can tolerate. There are four main ways this damage occurs: barotrauma, volutrauma, atelectrauma, and biotrauma [8]. Although these processes are often described individually, the effects are compounded by one another [9].

Barotrauma results from alveolar pressures that exceed the structural limits of the lung, producing direct mechanical disruption of the alveolar-capillary interface. The most recognizable consequences are pneumothorax, pneumomediastinum, and interstitial emphysema [10]. Although current practice is to limit plateau pressures to below 30 cm H<sub>2</sub>O, this threshold must be studied further [11]. Additionally, some regions of the lung may still be exposed to damaging pressures even when the ventilator parameters are within the recommended ranges [10].

In contrast, volutrauma refers to alveolar overdistension due to large tidal volumes. Overdistension disrupts epithelial and endothelial barriers, increases capillary leak, and results in pulmonary edema. Experimental methods have shown that these changes can occur even without elevated plateau pressures, suggesting that volume may be an independent cause of injury [10]. Clinically the ARDSnet trial demonstrated that using lower tidal volumes (6 mL/kg predicted body

weight) could significantly reduce mortality [7]. However, the specific lower limit of safe tidal volume remains up to debate, especially in patients without ARDS.

Atelectrauma describes the mechanical strain caused by repetitive alveolar collapse and reopening, often occurring in poorly recruited lung units. This cyclic opening and closing creates shear stress on epithelial surfaces, promoting edema and worsening gas exchange [12]. Furthermore, since surfactant function is impaired during mechanical ventilation, the risk of collapse of peripheral bronchioles at low lung volumes increases [13]. The resulting alveolar instability promotes uneven stress distribution and localized lung injury.

Biotrauma extends beyond structural injury to include the biological response triggered by mechanical forces. Overdistention and shear forces activate intracellular pathways resulting in the release of inflammatory mediators which amplify local inflammation and can disseminate systemically [14]. Although the concept of biotrauma has been demonstrated in both animal and human studies, the extent of its clinical effect remains disputed. Nonetheless, it highlights the physiological pathways that link mechanical ventilation to systemic disease processes.

### 2.2. Cellular and Molecular Responses

Among the many inflammatory mediators, cytokines such as interleukin-1 $\beta$  (IL-1 $\beta$ ), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) are consistently elevated in ventilator-induced injury models [15]. They have also been found to upregulate adhesion molecules, including E-selectins, P-selectins and ICAM-1, and initiate signaling pathways such as NF- $\kappa$ B and MAPK [16]. The resulting increase in alveolar-capillary permeability via cytokine-induced damage worsens pulmonary edema and gas exchange efficiency. Endogenous molecules have also been found to potentiate inflammation by activating pattern recognition receptors and cytokine release in response to lung tissue injury. Studies in both animals and humans have confirmed this process, showing elevated damage-associated molecular patterns in bronchoalveolar lavage fluid of patients with VILI and increased expression of pattern recognition receptors in ventilated lung tissue [17].

Oxidative stress also plays a key role in the development of VALI. Mechanical stretch and inflammatory signaling promote the release of reactive oxygen species (ROS) from alveolar macrophages and recruited neutrophils [16]. These ROS damage lipids, proteins, and deoxyribonucleic acid, while also activating transcription factors that increase cytokine production [16]. While there are natural antioxidant defenses such as glutathione, they are often overwhelmed in the setting of critical illness and prolonged ventilation.

The production of cytokines and ROS relies on the involvement of immune cells, predominantly neutrophils and macrophages. As explained, recruited neutrophils release proteases and oxidants, which disrupt alveolar architecture. Macrophages play a dual role, producing inflammatory cytokines in the acute phase, but later shifting toward tissue repair which may promote fibrotic remodeling [14]. Other immune populations including eosinophils and Th2 lymphocytes have also been linked to the release of cytokines [16].


### 2.3. Systemic Effects

Although initially a pulmonary process, VALI frequently extends beyond the lungs. Circulating cytokines, chemokines, and extracellular vesicles released from injured alveoli contribute to multiorgan dysfunction through various mechanisms, including systemic endocrine responses [18]. This systemic involvement has been linked to acute kidney injury, hepatic dysfunction, and cardiovascular compromise in both animal and clinical studies [19]. In addition, growing evidence highlights the connection between the coagulation cascade and inflammation in VALI. In primate models of sepsis-induced acute lung injury, targeting the intrinsic coagulation pathway reduced fibrin deposition, attenuated inflammation, and improved lung function [14].

In patients with preexisting systemic inflammation, such as from sepsis or systemic inflammatory response syndrome, VALI may be especially dangerous. Ventilation can exacerbate inflammation in septic patients by amplifying cytokine release, while in turn, systemic inflammation



lowers the threshold for ventilator-induced damage [20]. This bidirectional relationship helps explain the individualized risks and disproportionately high morbidity and mortality observed in septic patients requiring mechanical ventilation (Figure 2).



**Figure 2.** Role of immune cells in the pathophysiology of VALI. Created in BioRender. Khanyan, B. (2026) <https://biorender.com/fg4zyu8>

### 3. Risk Factors and Patient Susceptibility

Underlying lung diseases, such as ARDS and chronic obstructive pulmonary disease (COPD), have been found to increase a patient's risk of VALI. The ARDS lung is compared to "a small baby lung" due to the reduction in the number of functional alveoli during breaths. Ventilation with large tidal volumes has demonstrated an increase in morbidity and mortality in ARDS patients due to induced volutrauma [14]. Further, the variability of inflammatory change within the lungs in ARDS patients acts as a stressor that predisposes patients to lung injury. While positive end-expiratory pressure (PEEP) is needed to promote opening of alveoli, high PEEP levels can worsen lung stress and tension leading to VALI [21]. Further, although efforts have been made to reduce tidal volume and inspiratory pressures, mortality from lung injury in patients with ARDS remains elevated [22].

Similarly to ARDS, COPD and other obstructive diseases like asthma, have mechanical heterogeneity due to regional variability in factors such as bronchoconstriction and airway secretions. This makes patients with these lung diseases more vulnerable to lung injury [23]. COPD patients can have diaphragm and skeletal muscle weakness due to corticosteroid use and inflammation, increasing their length of duration on mechanical ventilation and putting them at greater risk for VALI [24]. Thus, underlying lung diseases, such as COPD and ARDS increase patient susceptibility to VALI.

VALI is also impacted by several other risk factors. Older age and comorbidities, such as pneumonia and immunosuppression, are risk factors for risk and severity of VALI [25]. There are also numerous ventilation parameters that predispose patients to VALI. High PEEP can lead to overdistention of the lung and hemodynamic impairment. High inspiratory flow rates can cause microvascular injury and diminish gas exchange. Increased inspiratory time has been found to reduce compliance and oxygenation and high inspiratory frequency increased perivascular hemorrhage in animal models [8]. Plateau and peak pressures and extended duration of mechanical ventilation have also been found to increase risk of VALI [22,26]. Neutrophil gelatinase-associated lipocalin, a key

marker in the innate immunologic response and inflammation, was found to be elevated in a time-dependent manner under mechanical ventilation [27].

## 4. Clinical Presentation and Diagnosis

### 4.1. Clinical Signs and Symptoms

Understanding the clinical signs and symptoms of VALI requires a foundational knowledge of its underlying pathophysiology. A key initial event in VALI is the acute inflammation of the alveolar-capillary membrane. This inflammation compromises the integrity of the barrier, resulting in the extravasation of protein-rich fluid into the alveolar spaces and interstitium [28]. The vascular component in the development of pulmonary edema is twofold. During lung inflation, the pressure in the interstitium surrounding the alveolar blood vessels decreases, while the transmural pressure within these vessels increases. This pressure differential promotes vascular dilation and leakage [9]. In addition, surfactant dysfunction contributes to alveolar collapse and reduced lung compliance, further exacerbating gas exchange abnormalities.

The hallmark clinical manifestation of VALI is pulmonary edema accompanied by impaired oxygenation. This is typically represented by hypoxemia, as reflected by a decline in arterial oxygen partial pressure, necessitating increased fractional inspired oxygen levels. Impaired alveolar ventilation may lead to the retention of carbon dioxide, resulting in respiratory acidosis. Conversely, in the early phases of lung injury, hyperventilation may cause hypocapnia.

Patients with VALI often present with tachypnea, the use of accessory respiratory muscles, and tachycardia [29]. However, these signs can be difficult to assess in mechanically ventilated patients. Furthermore, administration of high concentrations of oxygen can result in hyperoxia, which may induce oxidative alveolar injury [28]. Decreased lung compliance and/or increased airway resistance contribute to elevated peak and plateau airway pressures. Additional complications associated with VALI, particularly due to barotrauma, include pneumothorax, pneumomediastinum, and subcutaneous emphysema [9].

### 4.2. Radiographic Findings

Chest radiography in patients with VALI typically reveals bilateral alveolar and/or interstitial infiltrates. These infiltrates are often diffuse and may produce a characteristic “white lung” appearance. Importantly, a normal cardiac silhouette can help distinguish VALI from cardiogenic pulmonary edema [30]. Computed tomography imaging further elucidates the extent of lung injury. Common findings include patchy, heterogeneous areas of consolidation and atelectasis. Additionally, regions of hyperlucency may occasionally be observed, indicating areas of overdistension or air trapping.

### 4.3. Biomarkers

Mechanical stress imposed on the lungs during mechanical ventilation can activate inflammatory responses even in the absence of overt structural damage. This process, known as biotrauma, involves the release of pro-inflammatory cytokines, such as TNF- $\alpha$  and IL-6, as well as the recruitment of neutrophils and induction of oxidative stress. These events are mediated by mechanotransduction, a process whereby mechanical forces trigger intracellular signaling pathways, ultimately resulting in cellular activation and injury [28].

An effective biomarker would ideally quantify the extent of lung injury and guide therapeutic interventions. Elevated systemic levels of inflammatory markers such as TNF- $\alpha$ , IL-6, and IL-8 have been associated with adverse outcomes in patients with ARDS. However, these markers are not specific to VALI [28]. Recent investigations have explored more specific biomarkers for alveolar epithelial damage. The receptor for advanced glycation end products (RAGE), a marker of alveolar type I cell injury, has shown promise in this regard. Baseline plasma levels of RAGE correlate with

the severity of lung injury, and elevated levels have been associated with worse clinical outcomes in patients with acute lung injury. In a study by Calfee *et al.*, higher plasma RAGE concentrations were observed in patients ventilated with higher tidal volumes, while those ventilated with lower tidal volumes demonstrated a more significant decline in RAGE levels, suggesting a potential role for RAGE in monitoring ventilator-induced injury [31].

Similarly, surfactant protein D (SP-D), derived from alveolar type II cells, has also been proposed as a biomarker. Elevated plasma levels of SP-D have been linked to worse outcomes in lung injury. Importantly, patients ventilated with lower tidal volumes exhibited significantly lower SP-D levels, further supporting the protective effect of lung-protective ventilation strategies [32]. Although these biomarkers offer valuable insights into lung injury mechanisms, none are currently specific to VALI, limiting their utility in distinguishing VALI from other forms of lung inflammation or injury.

#### 4.4. Differentiating Ventilator-Associated Lung Injury from Disease Progression

VALI often presents with clinical features that closely resemble progressive pulmonary conditions such as ARDS, including refractory hypoxemia, diffuse bilateral infiltrates on imaging, and reduced lung compliance. Despite these similarities, the underlying pathophysiological mechanisms differ, making accurate differentiation essential for appropriate clinical management. VALI results from mechanical forces imposed by the ventilator, particularly barotrauma and volutrauma, which arises from alveolar overdistension associated with high tidal volumes. These processes disrupt the alveolar-capillary membrane, leading to increased permeability and the extravasation of protein-rich fluid into the alveoli [33]. Elevated transpulmonary pressures further exacerbate lung injury by amplifying mechanical stress, thereby promoting inflammation, pulmonary edema, and impaired gas exchange [10]. In contrast, disease progression in ARDS is primarily driven by intrinsic inflammatory or infectious etiologies, which may worsen despite lung-protective ventilation strategies [34]. Differentiating VALI from ARDS progression thus requires integrating ventilator parameters, clinical trajectory, imaging findings, and the patient's physiological response to supportive care.

## 5. Prevention and Protective Strategies

### 5.1. Lung-Protective Ventilation

ARDSNet, one of the most pivotal studies in the management of ARDS was conducted by the ARDS Network and published in 2000. This multicenter, randomized controlled trial enrolled 861 patients with ARDS, comparing the effects of traditional ventilation strategies using a tidal volume of 12 mL/kg of predicted body weight and plateau pressures  $\leq 50$  cm H<sub>2</sub>O versus a lung-protective strategy using a tidal volume of 6 mL/kg and plateau pressures  $\leq 30$  cm H<sub>2</sub>O [7]. The findings demonstrated a significant reduction in mortality with the low tidal volume strategy, showing an absolute survival benefit of approximately 9%. Additionally, patients in the low tidal volume group experienced shorter durations of mechanical ventilation and had lower levels of circulating inflammatory cytokines, suggesting a reduction in ventilator-induced lung injury [7]. Overall, these findings established low tidal volume ventilation as a fundamental strategy for reducing mortality and ventilator days in patients with acute lung injury and ARDS.

Lung-protective ventilation strategies are central to the management of ARDS, with low tidal volume ventilation and appropriate PEEP application forming the foundation of evidence-based practice. PEEP plays a critical role in improving oxygenation and minimizing atelectrauma. However, the optimal level of PEEP has been the subject of extensive investigation. Early randomized controlled trials comparing higher versus lower PEEP levels demonstrated improvements in oxygenation but failed to show a significant mortality benefit [35]. Building on these observations, subsequent research explored more comprehensive ventilation protocols.

Meade *et al.* investigated a multifaceted ventilatory approach incorporating low tidal volumes (6 mL/kg predicted body weight), plateau pressures limited to  $\leq 40$  cm H<sub>2</sub>O, recruitment maneuvers,

and higher PEEP to maintain an “open-lung” strategy. This approach was associated with improved oxygenation and a reduced need for rescue therapies, though it did not translate into a clear survival advantage [36]. Similarly, Mercat *et al.* tested the hypothesis that titrating PEEP to achieve higher alveolar recruitment could yield clinical benefits. While this strategy improved lung mechanics, enhanced oxygenation, and shortened the duration of mechanical ventilation, it did not significantly reduce mortality compared to conventional PEEP strategies [37].

Overall, these studies suggest that while higher PEEP may improve physiological parameters and reduce ventilator dependency, it does not consistently confer a survival advantage. Thus, the choice of PEEP should be individualized, balancing the potential benefits of alveolar recruitment against the risks of overdistension and hemodynamic compromise.

## 5.2. Adjunctive Therapies

Prone positioning is an adjunctive therapy that helps to reduce VALI through several mechanisms. By redistributing transpulmonary pressures more uniformly, it lessens regional stress and strain, enhances ventilation–perfusion matching, and limits overdistension in anterior lung regions [28]. Initial randomized controlled trials demonstrated improvements in oxygenation with prone positioning but did not consistently translate these physiological benefits into reduced mortality when compared with supine ventilation. A systematic review by Sud *et al.* reinforced this pattern, noting better oxygenation and a lower incidence of ventilator-associated pneumonia, though survival benefits remained uncertain [38]. The landmark PROSEVA trial altered this perspective by enrolling patients with severe ARDS and implementing early, prolonged prone sessions. In contrast to earlier studies, PROSEVA reported substantial reductions in both 28-day and 90-day mortality among patients managed in the prone position compared with supine ventilation [39]. These improvements were achieved without an increase in serious adverse events, although complications such as pressure injuries and airway-related issues remain possible. Current evidence therefore supports prone positioning as a standard component of care in severe ARDS, rather than a last-resort measure. Nonetheless, its specific role in attenuating VALI continues to warrant further study.

Patient–ventilator asynchrony has been associated with prolonged mechanical ventilation and worse clinical outcomes. Neuromuscular blocking agents (NMBAs) may help mitigate this effect by improving patient–ventilator synchrony. In a multicenter, randomized, double-blind trial involving 340 patients with severe ARDS, participants were assigned to receive either a 48-hour infusion of cisatracurium besylate, a neuromuscular blocking agent, or placebo. The study demonstrated an absolute reduction in 28-day mortality of 9.6% in the NMBA group compared with the control group ( $p = 0.05$ ), indicating significantly improved survival at both 28 and 90 days without an increased risk of ICU-acquired paresis [40]. Lung-protective ventilation strategies were applied in both groups. Additionally, patients receiving NMBAs experienced fewer days on mechanical ventilation, lower incidence of pneumothorax, reduced duration of ICU stay, and decreased occurrence of barotrauma [40]. These findings suggest that neuromuscular blockade may play a beneficial role in reducing VALI, but further studies are warranted to clarify optimal patient selection, timing, and duration of NMBA therapy to maximize clinical benefit while minimizing adverse effects.

Atelectasis is a common complication in mechanically ventilated patients and can be mitigated through the use of recruitment maneuvers. Recruitment maneuvers involve intermittent or sustained hyperinflation of the lungs to reopen collapsed alveoli, often combined with elevated PEEP to prevent re-collapse. These interventions serve as valuable adjuncts to low tidal volume ventilation, helping to reduce the risk of atelectrauma. The most frequently employed recruitment maneuver is sustained inflation. However, this approach carries potential adverse effects, including barotrauma, alveolar overdistension, and hemodynamic instability. Recent strategies, such as pressure-controlled ventilation with gradual or incremental PEEP increases, have been proposed to minimize these risks [41].

In a large randomized controlled trial comparing conventional low tidal volume ventilation to an “open lung” approach—which combined low tidal volume, higher PEEP, and recruitment



maneuvers—the addition of recruitment maneuvers did not significantly affect overall mortality, duration of mechanical ventilation, or incidence of barotrauma. Nevertheless, the open lung strategy was associated with reduced need for rescue therapies and fewer deaths due to refractory hypoxemia [36]. Current evidence supports the use of recruitment maneuvers primarily as a method to optimize PEEP settings or as a rescue intervention in cases of severe hypoxemia, rather than as a routine, standalone procedure [41]. Consequently, while recruitment maneuvers can be a beneficial adjunct in selected patients with severe hypoxemia, their routine application is limited by the potential for barotrauma and cardiovascular complications.

### 5.3. Non-Ventilatory Strategies

Pulmonary edema represents a major component of VALI, highlighting the critical role of fluid management in modulating its development and progression. Evidence suggests that judicious fluid management can reduce the incidence of pulmonary edema and increase the number of ventilator-free days [42]. However, inadequate fluid resuscitation in mechanically ventilated patients may lead to hypovolemia, which in turn can precipitate multiple organ failure [6]. Furthermore, research indicates that age-related susceptibility influences the severity of VALI-induced pulmonary edema. Older patients are not only more prone to injury but are also more likely to experience downstream complications and increased mortality [43]. These findings underscore the importance of achieving an optimal balance in fluid management to improve patient outcomes and reduce the risk of ventilator-associated complications.

Although there is limited literature regarding early weaning protocols and sedation minimization in VALI, emerging evidence supports their potential benefits in mechanically ventilated patients. A clinical trial involving 104 adults investigated whether the early initiation of physical and occupational therapy, combined with daily sedation interruptions, could improve recovery outcomes in the ICU. The study found that 59% of patients in the early therapy group regained independent functional status—defined as the ability to walk unassisted and perform six activities of daily living—by hospital discharge, compared with 35% in the control group ( $p = 0.02$ ; odds ratio 2.7, 95% CI 1.2–6.1). Moreover, patients in the intervention group experienced a greater number of ventilator-free days within the first 28 days (median 23.5 days vs. 21.1 days,  $p = 0.05$ ) [44]. These findings indicate that the early implementation of structured mobilization alongside sedation minimization is a safe and effective strategy to enhance both physical and neurocognitive recovery in critically ill patients.

## 6. Emerging Therapies and Research

### 6.1. Personalized Ventilation Strategies

Traditional lung-protective strategies, such as low tidal volumes and limiting plateau pressures, have improved outcomes in ARDS, yet mortality remains high. To further advance care, researchers are exploring personalized mechanical ventilation tailored to each patient's physiology and lung morphology. The LIVE study demonstrated that aligning tidal volumes, PEEP, prone positioning, and recruitment with “focal” and “non-focal” ARDS subphenotypes could reduce mortality when morphology was accurately classified [45]. However, benefits were obscured by frequent misclassification. The PEGASUS trial (Personalized Mechanical Ventilation Guided by Ultrasound in ARDS) will be the first randomized controlled trial to evaluate lung ultrasound-guided personalized ventilation compared with conventional strategies in moderate to severe ARDS [46]. It plans to enroll 538 patients that are mechanically ventilated in an ICU setting with moderate to severe ARDS.

Additional targets of ventilator personalization are under investigation. Transpulmonary pressure, derived from airway and pleural pressure estimates, reflects the lung's true distending force and can guide individualized adjustment of PEEP, inspiratory limits, and recruitment maneuvers, though robust trial evidence remains limited [47]. Mechanical power, representing the cumulative energy delivered from the ventilator to the lungs, integrates tidal volume, pressure, flow,

resistance, and respiratory rate. Restricting mechanical power has been proposed to limit VILI, as exceeding critical thresholds accelerates damage. However, uncertainty persists regarding calculation methods, validated thresholds, and randomized controlled trial confirmation [22]. Despite promising concepts, meta-analyses show no significant mortality benefit from image-guided, driving-pressure, or transpulmonary pressure-based personalization [48].

### 6.2. Artificial Intelligence and Closed-Loop Ventilators

Artificial intelligence (AI) and closed-loop ventilator modes are emerging as promising tools for preventing and managing VALI. Both approaches aim to deliver individualized, adaptive, and lung-protective ventilation strategies that extend beyond the limitations of conventional methods. AI has the potential to optimize and personalize mechanical ventilation by continuously integrating patient-specific physiological data to guide clinical decisions. Current research has largely focused on applications such as predicting clinical outcomes, assessing readiness for weaning, and improving extubation success [49].

Closed-loop ventilation operates through feedback mechanisms that automatically adjust ventilator outputs to match the needs of each patient. In this model, clinicians set target parameters, while the ventilator fine-tunes its settings in real time. One widely studied system, IntelliVent-ASV®, adjusts minute ventilation based on end-tidal carbon dioxide levels and modifies oxygen delivery according to peripheral oxygen saturation. In a randomized controlled trial, IntelliVent-ASV® was shown to provide safe and effective ventilation [50,51].

Another promising approach is time-controlled adaptive ventilation (TCAV), a closed-loop application of airway pressure release ventilation. TCAV individualizes expiratory duration based on lung compliance, aiming to stabilize alveoli and gradually reopen collapsed regions. By adapting to the dynamic pathophysiology of ARDS, TCAV may reduce VILI and improve patient outcomes [52].

### 6.3. Pharmacological Interventions Targeting Inflammation

Targeting inflammatory pathways with pharmacological therapies offers a promising approach to reducing VALI and improving patient outcomes. Damage-associated molecular patterns (DAMPs) are released during tissue injury and may contribute to VALI. DAMPs activate pattern recognition receptors that drive nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B)-mediated inflammation. Though low concentrations of DAMPs promote tissue repair, their increased release promotes lung damage, which indicates the bidirectional function of DAMPs in inflammation. Experimental data reveal that DAMP signaling is a target for anti-inflammatory inhibition and improved results [17]. The endothelial Yes-associated protein (YAP) can also be targeted pharmacologically. Through its stabilization of vascular endothelial cadherin (VE-cadherin), endothelial integrity can be sustained, which then can reduce vascular leakage and neutrophil invasion, showing its potential as a therapeutic target [53].

Multiple pharmacological agents have been shown to reduce inflammatory markers, potentially reducing the risk for VALI. Commonly used anesthetics like isoflurane, sevoflurane, and propofol have anti-inflammatory effects via their reduction of cytokine release [20]. Similarly, remimazolam, a relatively new sedative, shows promise in targeting inflammation by limiting macrophage pyroptosis, reducing cytokine release, and preserving alveolar structure through translocator protein (TSPO) activation in preclinical studies utilizing mouse models of VILI [54]. In a meta-analysis of 20 randomized controlled trials, dexmedetomidine demonstrated anti-inflammatory effects by lowering inflammatory cytokines and improving oxygen levels in patients undergoing one-lung ventilation. The findings indicate that dexmedetomidine could be a promising anti-inflammatory option, though larger trials are needed [55]. Overall, these strategies demonstrate the potential of pharmacological treatments to reduce inflammation in VALI. However, most are still experimental and need more validation in clinical practice.

#### 6.4. Stem Cell Therapies and Tissue Repair Mechanisms

Stem-cell therapies, particularly mesenchymal stem cells (MSCs), are promising agents in VALI prevention and therapy by promoting regeneration, modulating inflammation, and repairing lung tissue, as evidenced by various preclinical and clinical studies. Preclinical models have demonstrated that intravenous MSC therapy can improve oxygenation and compliance, reduce edema and inflammation, and restore lung architecture in VILI rat models [56], suggesting potential therapeutic benefits for VALI. Early clinical trials have shown potential benefits of MSC therapy, such as reduced lung lesion volume in severe COVID-19 cases. In a phase 2 randomized, double-blind trial in severe COVID-19, human umbilical cord MSCs significantly reduced solid lung lesion volume compared with placebo. However, the effects on mortality and long-term function remain unclear [57]. Similarly, a pilot trial of adipose-derived MSCs in ARDS found the treatment to be safe, but it showed no significant differences in ventilator-free days, or ICU stay compared to placebo [58]. Larger trials are needed to confirm benefits, refine dosing, and determine optimal cell sources and delivery strategies [59].

## 7. Controversies and Challenges

### 7.1. Optimal PEEP Levels and Individualized Settings

The optimal level of PEEP in VALI continues to be debated. Although higher PEEP may enhance alveolar recruitment and reduce atelectrauma, it can risk alveolar overdistension, contributing to lung injury. Thus, there is growing consensus that PEEP has to be adjusted according to each patient's lung physiology. One approach to personalization was tested in a retrospective cohort study that utilized esophageal manometry to guide PEEP settings based on transpulmonary pressure in obese, mechanically ventilated patients. This method allowed clinicians to tailor ventilation to patient-specific needs. Results of this study included lower driving pressures, and improved oxygenation, with no significant adverse events reported [60].

Electrical impedance tomography (EIT) represents another promising method for optimizing PEEP at bedside. This non-invasive, radiation-free technique provides real-time monitoring of regional ventilation [61]. A recent meta-analysis demonstrated that ARDS patients managed with EIT-guided PEEP had lower mortality compared to conventional ventilation, although no improvements in other clinical outcomes were noted [62].

### 7.2. Use of High-Frequency Oscillatory Ventilation

High-frequency oscillatory ventilation (HFOV) continues to be a topic of discussion in preventing VALI. Unlike conventional mechanical ventilation, HFOV delivers extremely small tidal volumes at very rapid respiratory rates using an oscillating piston pump. HFOV's approach helps maintain oxygenation by sustaining higher mean airway pressures while limiting large changes in alveolar pressure, with the goal of keeping the lungs open and reducing injury [63]. HFOV was initially developed to avoid the potentially damaging volume and pressure fluctuations seen with standard ventilation. Theoretically, HFOV is particularly well-suited for surfactant-deficient infants, as it may promote more effective alveolar recruitment [15]. Clinical studies in premature infants support the benefits of HFOV since early application of HFOV has been linked to reduced cytokine-driven inflammation [64]. These findings suggest that HFOV may have meaningful benefits in carefully selected neonatal populations.

Evidence in adults, however, has been far less convincing. HFOV is primarily used as a rescue strategy in cases of severe, refractory hypoxemia, although its role in the routine management of ARDS remains uncertain [28]. Due to the limited number and relative homogeneity of adult studies, its impact on VALI and mortality in ARDS remains unproven [9]. A large multicenter trial that randomized adults with ARDS to receive either HFOV or conventional ventilation found no

difference in 30-day mortality between groups, indicating that HFOV offers no clear survival advantage over standard care [65].

### 7.3. Debates Around Permissive Hypercapnia

Permissive hypercapnia has been utilized as a potential strategy in managing VALI. Low tidal volume ventilation, one of the cornerstones of lung-protective ventilatory strategies, often results in hypercapnia and can contribute to the development of hypercapnic acidosis, rendering permissive hypercapnia a valid option to consider [9]. Preclinical trials using rat models have shown that together, permissive hypercapnia and lung-protective ventilation could provide protection against VALI [66]. In a single center, a cohort of 38 immunocompromised children with severe ARDS underwent a ventilatory strategy allowing high arterial partial pressure of carbon dioxide (up to 140 mmHg) to facilitate low tidal volumes and low pressures. The study concluded that this ventilatory strategy was feasible and well tolerated in a majority of cases [67]. The secondary analysis of three large prospective ARDS cohort studies also found that severe hypercapnia (arterial partial pressure of carbon dioxide  $\geq 50$  mmHg) was independently associated with increased ICU mortality in moderate and severe ARDS patients, proposing the potential risks of permissive hypercapnia for certain patient populations [68]. These study results suggest that while permissive hypercapnia has protective benefits in some groups, it would potentially be harmful in others, thereby necessitating the need for prudent patient selection.

### 7.4. Ventilation in COVID-19 and Lessons Learned

At the start of the COVID-19 pandemic, some clinicians turned to non-invasive ventilation due to a concern that endotracheal intubation may worsen outcomes. Evidence was conflicting: one study reported earlier intubation had better survival [69], whereas another found higher 60-day mortality [70]. Non-invasive ventilatory strategies allowed patients with moderate respiratory insufficiency to avoid intubation and potentially reduce VALI risk, at least for a certain amount of time. This was especially important as barotrauma occurred more often in COVID-19 ARDS than in other forms of ARDS, with an incidence of about one in every six ventilated patients [71,72]. If endotracheal intubation was unavoidable, compliance with lung-protective strategies, low tidal volumes, plateau pressures below 30 cm H<sub>2</sub>O, and gentle titration of PEEP, were the safest and most effective approach [73].

## 8. Conclusions

Advances in critical care medicine in the last two decades have elucidated the major mechanisms of VALI, and clinical evidence has established that prevention via lung-protective ventilation strategies improves outcomes in patients with and without ARDS. Nonetheless, VALI remains a major contributor in morbidity and mortality in critically ill patients necessitating mechanical ventilation. Thus, further research is needed to shed light on optimal preventative measures, systemic effects and patient-specific susceptibility. Future directions include precision medicine approaches, integration of genomics and biomarkers, and translational research advances. Given the heterogeneity in lung mechanics, alveoli recruitability and inflammatory responses among patients with VALI, advances in precision medicine are moving away from a general to an individualized approach to medical therapeutics. Esophageal manometry, individualized dynamic PEEP titration, and EIT represent current emerging tools to tailor ventilation strategies to each patient's physiology and pathophysiology, allowing for a potential reduction in VALI.

Advances in genomics and biomarkers of endothelial injury and inflammatory mediators may confer opportunities to identify patients at increased risk of VALI during the early injury phase, thus potentially reducing the development of VALI and improving morbidity and mortality in critically ill patients. Real-time biomarker-guided ventilation strategies may then be coupled with precision medicine to implement dynamic ventilatory measures tailored to the patient's specific physiology.



Furthermore, developments in translational research are needed to apply promising preclinical data to improved clinical outcomes. Novel technologies like smart ventilators, AI and machine-learning-based predictive models have the potential to minimize iatrogenic lung injury while conferring ventilatory support as a life-saving measure. Until these advancements are translated into sound clinical outcomes, the current strategy to prevent VALI focuses on lung-protective ventilation strategies, careful fluid balance, and adjunctive therapies such as prone positioning, use of NMBAs, and sedation minimization. Further understanding and prevention of VALI will contribute to improved outcomes in ARDS and safer mechanical ventilation measures for critically ill patients.

**Author Contributions:** Conceptualization, A.C. and S.B.; methodology, A.C.; writing—original draft preparation, A.C., B.S., S.G., B.K. and P.L.; writing—review and editing, A.C., B.S., S.G., B.K., P.L. and S.B.; visualization, A.C. and B.K.; supervision, A.C. and S.B.; project administration, A.C. and S.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No new data were created.

**Acknowledgments:** Sery Pak, graphical abstract (Figure 1).

**Conflicts of Interest:** The authors declare no conflicts of interest.

## Abbreviations

The following abbreviations are used in this manuscript:

ARDS	Acute respiratory distress syndrome
AI	Artificial intelligence
COPD	Chronic obstructive pulmonary disease
DAMPs	Damage-associated molecular patterns
EIT	Electrical impedance tomography
ICU	Intensive care unit
HFOV	High-frequency oscillatory ventilation
IL-1 $\beta$	Interleukin-1 $\beta$
IL-6	Interleukin-6
IL-8	Interleukin-8
MSCs	Mesenchymal stem cells
NK- $\kappa$ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
NMBAs	Neuromuscular blocking agents
PEEP	Positive end-expiratory pressure
RAGE	Receptor for advanced glycation end products
ROS	Reactive oxygen species
SP-D	Surfactant protein D
TCAV	Time-controlled adaptive ventilation
TNF- $\alpha$	Tumor necrosis factor--alpha
TSPO	Translocator protein
VALI	Ventilator associated lung injury
VE-cadherin	Vascular endothelial cadherin
VILI	Ventilator induced lung injury
YAP	Yes-associated protein

## References

1. Pinhu, L.; Whitehead, T.; Evans, T.; Griffiths, M. Ventilator-associated lung injury. *Lancet* **2003**, *361*, 332-340, doi:10.1016/S0140-6736(03)12329-X.

2. International consensus conferences in intensive care medicine: Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societe de Reanimation de Langue Francaise, and was approved by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* **1999**, *160*, 2118-2124, doi:10.1164/ajrccm.160.6.ats16060.
3. Gajic, O.; Dara, S.I.; Mendez, J.L.; Adesanya, A.O.; Festic, E.; Caples, S.M.; Rana, R.; St Sauver, J.L.; Lymp, J.F.; Afessa, B.; et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. *Crit Care Med* **2004**, *32*, 1817-1824, doi:10.1097/01.ccm.0000133019.52531.30.
4. Bellani, G.; Laffey, J.G.; Pham, T.; Fan, E.; Brochard, L.; Esteban, A.; Gattinoni, L.; van Haren, F.; Larsson, A.; McAuley, D.F.; et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA* **2016**, *315*, 788-800, doi:10.1001/jama.2016.0291.
5. Rubenfeld, G.D.; Caldwell, E.; Peabody, E.; Weaver, J.; Martin, D.P.; Neff, M.; Stern, E.J.; Hudson, L.D. Incidence and outcomes of acute lung injury. *N Engl J Med* **2005**, *353*, 1685-1693, doi:10.1056/NEJMoa050333.
6. Plotz, F.B.; Slutsky, A.S.; van Vught, A.J.; Heijnen, C.J. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. *Intensive Care Med* **2004**, *30*, 1865-1872, doi:10.1007/s00134-004-2363-9.
7. Acute Respiratory Distress Syndrome, N.; Brower, R.G.; Matthay, M.A.; Morris, A.; Schoenfeld, D.; Thompson, B.T.; Wheeler, A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* **2000**, *342*, 1301-1308, doi:10.1056/NEJM200005043421801.
8. Rocco, P.R.; Dos Santos, C.; Pelosi, P. Pathophysiology of ventilator-associated lung injury. *Curr Opin Anaesthesiol* **2012**, *25*, 123-130, doi:10.1097/ACO.0b013e32834f8c7f.
9. Kuchnicka, K.; Maciejewski, D. Ventilator-associated lung injury. *Anaesthesiol Intensive Ther* **2013**, *45*, 164-170, doi:10.5603/AIT.2013.0034.
10. Slutsky, A.S.; Ranieri, V.M. Ventilator-induced lung injury. *N Engl J Med* **2013**, *369*, 2126-2136, doi:10.1056/NEJMra1208707.
11. Gattinoni, L.; Giosa, L.; Bonifazi, M.; Pasticci, I.; Busana, M.; Macri, M.; Romitti, F.; Vassalli, F.; Quintel, M. Targeting transpulmonary pressure to prevent ventilator-induced lung injury. *Expert Rev Respir Med* **2019**, *13*, 737-746, doi:10.1080/17476348.2019.1638767.
12. Gattinoni, L.; Protti, A.; Caironi, P.; Carlesso, E. Ventilator-induced lung injury: the anatomical and physiological framework. *Crit Care Med* **2010**, *38*, S539-548, doi:10.1097/CCM.0b013e3181f1fcf7.
13. Tsumura, H.; Harris, E.; Brandon, D.; Pan, W.; Vacchiano, C. Review of the Mechanisms of Ventilator Induced Lung Injury and the Principles of Intraoperative Lung Protective Ventilation. *AANA J* **2021**, *89*, 227-233.
14. Oeckler, R.A.; Hubmayr, R.D. Ventilator-associated lung injury: a search for better therapeutic targets. *Eur Respir J* **2007**, *30*, 1216-1226, doi:10.1183/09031936.00104907.
15. Carvalho, C.G.; Silveira, R.C.; Procianoy, R.S. Ventilator-induced lung injury in preterm infants. *Rev Bras Ter Intensiva* **2013**, *25*, 319-326, doi:10.5935/0103-507X.20130054.
16. Belperio, J.A.; Keane, M.P.; Lynch, J.P., 3rd; Strieter, R.M. The role of cytokines during the pathogenesis of ventilator-associated and ventilator-induced lung injury. *Semin Respir Crit Care Med* **2006**, *27*, 350-364, doi:10.1055/s-2006-948289.
17. Kuipers, M.T.; van der Poll, T.; Schultz, M.J.; Wieland, C.W. Bench-to-bedside review: Damage-associated molecular patterns in the onset of ventilator-induced lung injury. *Crit Care* **2011**, *15*, 235, doi:10.1186/cc10437.
18. Penesova, A.; Galusova, A.; Vligas, M.; Vlcek, M.; Imrich, R.; Majek, M. The role of endocrine mechanisms in ventilator-associated lung injury in critically ill patients. *Endocr Regul* **2012**, *46*, 161-166, doi:10.4149/endo\_2012\_03\_161.
19. Imai, Y.; Parodo, J.; Kajikawa, O.; de Perrot, M.; Fischer, S.; Edwards, V.; Cutz, E.; Liu, M.; Keshavjee, S.; Martin, T.R.; et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ

- dysfunction in an experimental model of acute respiratory distress syndrome. *JAMA* **2003**, *289*, 2104-2112, doi:10.1001/jama.289.16.2104.
20. Chen, L.; Zhao, H.; Alam, A.; Mi, E.; Eguchi, S.; Yao, S.; Ma, D. Postoperative remote lung injury and its impact on surgical outcome. *BMC Anesthesiol* **2019**, *19*, 30, doi:10.1186/s12871-019-0698-6.
  21. Merola, R.; Vargas, M.; Battaglini, D. Ventilator-Induced Lung Injury: The Unseen Challenge in Acute Respiratory Distress Syndrome Management. *J Clin Med* **2025**, *14*, doi:10.3390/jcm14113910.
  22. von Düring, S.; Parhar, K.K.S.; Adhikari, N.K.J.; Urner, M.; Kim, S.J.; Munshi, L.; Liu, K.; Fan, E. Understanding ventilator-induced lung injury: The role of mechanical power. *J Crit Care* **2025**, *85*, 154902, doi:10.1016/j.jcrc.2024.154902.
  23. Marini, J.J. Ventilator-associated problems related to obstructive lung disease. *Respir Care* **2013**, *58*, 938-949, doi:10.4187/respcare.02242.
  24. Rouze, A.; Cottreau, A.; Nseir, S. Chronic obstructive pulmonary disease and the risk for ventilator-associated pneumonia. *Curr Opin Crit Care* **2014**, *20*, 525-531, doi:10.1097/MCC.000000000000123.
  25. Zhu, S.; Wang, W.; Kang, Y.; He, Q.; Zhang, H.; Deng, Y.; Cai, L.; Zhang, R.; Sun, X.; Zong, Z. Clinical outcomes and risk factors for mortality from ventilator-associated events: A registry-based cohort study among 30,830 intensive care unit patients. *Infect Control Hosp Epidemiol* **2022**, *43*, 48-55, doi:10.1017/ice.2021.64.
  26. Marini, J.J.; Rocco, P.R.M.; Gattinoni, L. Static and Dynamic Contributors to Ventilator-induced Lung Injury in Clinical Practice. Pressure, Energy, and Power. *Am J Respir Crit Care Med* **2020**, *201*, 767-774, doi:10.1164/rccm.201908-1545CI.
  27. Xiao, R.; Chen, R. Neutrophil gelatinase-associated lipocalin as a potential novel biomarker for ventilator-associated lung injury. *Mol Med Rep* **2017**, *15*, 3535-3540, doi:10.3892/mmr.2017.6442.
  28. Salman, D.; Finney, S.J.; Griffiths, M.J. Strategies to reduce ventilator-associated lung injury (VALI). *Burns* **2013**, *39*, 200-211, doi:10.1016/j.burns.2012.10.013.
  29. Matuschak, G.M.; Lechner, A.J. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. *Mo Med* **2010**, *107*, 252-258.
  30. Anjum, A.K.A.F. Ventilator-Induced Lung Injury (VILI). **2023**.
  31. Calfee, C.S.; Ware, L.B.; Eisner, M.D.; Parsons, P.E.; Thompson, B.T.; Wickersham, N.; Matthay, M.A.; Network, N.A. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. *Thorax* **2008**, *63*, 1083-1089, doi:10.1136/thx.2008.095588.
  32. Eisner, M.D.; Parsons, P.; Matthay, M.A.; Ware, L.; Greene, K.; Acute Respiratory Distress Syndrome, N. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. *Thorax* **2003**, *58*, 983-988, doi:10.1136/thorax.58.11.983.
  33. de Prost, N.; Ricard, J.D.; Saumon, G.; Dreyfuss, D. Ventilator-induced lung injury: historical perspectives and clinical implications. *Ann Intensive Care* **2011**, *1*, 28, doi:10.1186/2110-5820-1-28.
  34. Thompson, B.T.; Chambers, R.C.; Liu, K.D. Acute Respiratory Distress Syndrome. *N Engl J Med* **2017**, *377*, 562-572, doi:10.1056/NEJMra1608077.
  35. Brower, R.G.; Lanken, P.N.; MacIntyre, N.; Matthay, M.A.; Morris, A.; Ancukiewicz, M.; Schoenfeld, D.; Thompson, B.T.; National Heart, L.; Blood Institute, A.C.T.N. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* **2004**, *351*, 327-336, doi:10.1056/NEJMoa032193.
  36. Meade, M.O.; Cook, D.J.; Guyatt, G.H.; Slutsky, A.S.; Arabi, Y.M.; Cooper, D.J.; Davies, A.R.; Hand, L.E.; Zhou, Q.; Thabane, L.; et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* **2008**, *299*, 637-645, doi:10.1001/jama.299.6.637.
  37. Mercat, A.; Richard, J.C.; Vielle, B.; Jaber, S.; Osman, D.; Diehl, J.L.; Lefrant, J.Y.; Prat, G.; Richecoeur, J.; Nieszkowska, A.; et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* **2008**, *299*, 646-655, doi:10.1001/jama.299.6.646.

38. Sud, S.; Sud, M.; Friedrich, J.O.; Adhikari, N.K. Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. *CMAJ* **2008**, *178*, 1153-1161, doi:10.1503/cmaj.071802.
39. Guerin, C.; Reignier, J.; Richard, J.C.; Beuret, P.; Gacouin, A.; Boulain, T.; Mercier, E.; Badet, M.; Mercat, A.; Baudin, O.; et al. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* **2013**, *368*, 2159-2168, doi:10.1056/NEJMoa1214103.
40. Papazian, L.; Forel, J.M.; Gacouin, A.; Penot-Ragon, C.; Perrin, G.; Loundou, A.; Jaber, S.; Arnal, J.M.; Perez, D.; Seghboyan, J.M.; et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* **2010**, *363*, 1107-1116, doi:10.1056/NEJMoa1005372.
41. Rocco, P.R.; Pelosi, P.; de Abreu, M.G. Pros and cons of recruitment maneuvers in acute lung injury and acute respiratory distress syndrome. *Expert Rev Respir Med* **2010**, *4*, 479-489, doi:10.1586/ers.10.43.
42. Valentine, S.L.; Sapru, A.; Higgerson, R.A.; Spinella, P.C.; Flori, H.R.; Graham, D.A.; Brett, M.; Convery, M.; Christie, L.M.; Karamessinis, L.; et al. Fluid balance in critically ill children with acute lung injury. *Crit Care Med* **2012**, *40*, 2883-2889, doi:10.1097/CCM.0b013e31825bc54d.
43. Herbert, J.A.; Valentine, M.S.; Saravanan, N.; Schneck, M.B.; Pidaparti, R.; Fowler, A.A., 3rd; Reynolds, A.M.; Heise, R.L. Conservative fluid management prevents age-associated ventilator induced mortality. *Exp Gerontol* **2016**, *81*, 101-109, doi:10.1016/j.exger.2016.05.005.
44. Schweickert, W.D.; Pohlman, M.C.; Pohlman, A.S.; Nigos, C.; Pawlik, A.J.; Esbrook, C.L.; Spears, L.; Miller, M.; Franczyk, M.; Deprizio, D.; et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* **2009**, *373*, 1874-1882, doi:10.1016/S0140-6736(09)60658-9.
45. Constantin, J.M.; Jabaudon, M.; Lefrant, J.Y.; Jaber, S.; Quenot, J.P.; Langeron, O.; Ferrandiere, M.; Grelon, F.; Seguin, P.; Ichai, C.; et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. *Lancet Respir Med* **2019**, *7*, 870-880, doi:10.1016/S2213-2600(19)30138-9.
46. Sinnige, J.S.; Smit, M.R.; Ghose, A.; de Grooth, H.J.; Itenov, T.S.; Ischaki, E.; Laffey, J.; Paulus, F.; Pova, P.; Pierrakos, C.; et al. Personalized mechanical ventilation guided by ultrasound in patients with acute respiratory distress syndrome (PEGASUS): study protocol for an international randomized clinical trial. *Trials* **2024**, *25*, 308, doi:10.1186/s13063-024-08140-7.
47. Pelosi, P.; Ball, L.; Barbas, C.S.V.; Bellomo, R.; Burns, K.E.A.; Einav, S.; Gattinoni, L.; Laffey, J.G.; Marini, J.J.; Myatra, S.N.; et al. Personalized mechanical ventilation in acute respiratory distress syndrome. *Crit Care* **2021**, *25*, 250, doi:10.1186/s13054-021-03686-3.
48. Munoz, J.; Cedeno, J.A.; Castaneda, G.F.; Visedo, L.C. Personalized ventilation adjustment in ARDS: A systematic review and meta-analysis of image, driving pressure, transpulmonary pressure, and mechanical power. *Heart Lung* **2024**, *68*, 305-315, doi:10.1016/j.hrtlng.2024.08.013.
49. Misseri, G.; Piattoli, M.; Cuttone, G.; Gregoretti, C.; Bignami, E.G. Artificial Intelligence for Mechanical Ventilation: A Transformative Shift in Critical Care. *Ther Adv Pulm Crit Care Med* **2024**, *19*, 29768675241298918, doi:10.1177/29768675241298918.
50. Arnal, J.M.; Wysocki, M.; Novotni, D.; Demory, D.; Lopez, R.; Donati, S.; Granier, I.; Corno, G.; Durand-Gasselino, J. Safety and efficacy of a fully closed-loop control ventilation (IntelliVent-ASV(R)) in sedated ICU patients with acute respiratory failure: a prospective randomized crossover study. *Intensive Care Med* **2012**, *38*, 781-787, doi:10.1007/s00134-012-2548-6.
51. Bialais, E.; Wittebole, X.; Vignaux, L.; Roeseler, J.; Wysocki, M.; Meyer, J.; Reyckler, G.; Novotni, D.; Sottiaux, T.; Laterre, P.F.; et al. Closed-loop ventilation mode (IntelliVent(R)-ASV) in intensive care unit: a randomized trial. *Minerva Anestesiol* **2016**, *82*, 657-668.
52. Al-Khalisy, H.; Nieman, G.F.; Kollisch-Singule, M.; Andrews, P.; Camporota, L.; Shiber, J.; Manouagian, T.; Satalin, J.; Blair, S.; Ghosh, A.; et al. Time-Controlled Adaptive Ventilation (TCAV): a personalized strategy for lung protection. *Respir Res* **2024**, *25*, 37, doi:10.1186/s12931-023-02615-y.



53. Su, K.; Wang, J.; Lv, Y.; Tian, M.; Zhao, Y.Y.; Minshall, R.D.; Hu, G. YAP expression in endothelial cells prevents ventilator-induced lung injury. *Am J Physiol Lung Cell Mol Physiol* **2021**, *320*, L568-L582, doi:10.1152/ajplung.00472.2020.
54. Zhang, L.; Zhao, D.; Lv, H.; Jiang, X. Remimazolam Alleviates Ventilator-Induced Lung Injury by Activating TSP0 to Inhibit Macrophage Pyroptosis. *Discov Med* **2024**, *36*, 1600-1609, doi:10.24976/Discov.Med.202436187.146.
55. Bai, Y.X.; Zhang, J.H.; Zhao, B.C.; Liu, K.X.; Bai, Y.W. Dexmedetomidine attenuates one-lung ventilation associated lung injury by suppressing inflammatory responses: A systematic review and meta-analysis. *Clin Exp Pharmacol Physiol* **2021**, *48*, 1203-1214, doi:10.1111/1440-1681.13525.
56. Curley, G.F.; Hayes, M.; Ansari, B.; Shaw, G.; Ryan, A.; Barry, F.; O'Brien, T.; O'Toole, D.; Laffey, J.G. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. *Thorax* **2012**, *67*, 496-501, doi:10.1136/thoraxjnl-2011-201059.
57. Shi, L.; Huang, H.; Lu, X.; Yan, X.; Jiang, X.; Xu, R.; Wang, S.; Zhang, C.; Yuan, X.; Xu, Z.; et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. *Signal Transduct Target Ther* **2021**, *6*, 58, doi:10.1038/s41392-021-00488-5.
58. Zheng, G.; Huang, L.; Tong, H.; Shu, Q.; Hu, Y.; Ge, M.; Deng, K.; Zhang, L.; Zou, B.; Cheng, B.; et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respir Res* **2014**, *15*, 39, doi:10.1186/1465-9921-15-39.
59. Wang, W.; Lei, W.; Jiang, L.; Gao, S.; Hu, S.; Zhao, Z.G.; Niu, C.Y.; Zhao, Z.A. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. *J Transl Med* **2021**, *19*, 198, doi:10.1186/s12967-021-02862-x.
60. Liou, J.; Doherty, D.; Gillin, T.; Emberger, J.; Yi, Y.; Cardenas, L.; Benninghoff, M.; Vest, M.; Deitchman, A. Retrospective Review of Transpulmonary Pressure Guided Positive End-Expiratory Pressure Titration for Mechanical Ventilation in Class II and III Obesity. *Crit Care Explor* **2022**, *4*, e0690, doi:10.1097/CCE.0000000000000690.
61. Muders, T.; Luepschen, H.; Putensen, C. Impedance tomography as a new monitoring technique. *Curr Opin Crit Care* **2010**, *16*, 269-275, doi:10.1097/MCC.0b013e3283390cbf.
62. Sanchez-Piedra, C.; Rodriguez-Ortiz-de-Salazar, B.; Roca, O.; Prado-Galbarro, F.J.; Perestelo-Perez, L.; Sanchez-Gomez, L.M. Electrical impedance tomography for PEEP titration in ARDS patients: a systematic review and meta-analysis. *J Clin Monit Comput* **2025**, doi:10.1007/s10877-025-01266-2.
63. Stewart, N.I.; Jagelman, T.A.; Webster, N.R. Emerging modes of ventilation in the intensive care unit. *Br J Anaesth* **2011**, *107*, 74-82, doi:10.1093/bja/aer114.
64. Dani, C.; Bertini, G.; Pezzati, M.; Filippi, L.; Pratesi, S.; Caviglioli, C.; Rubaltelli, F.F. Effects of pressure support ventilation plus volume guarantee vs. high-frequency oscillatory ventilation on lung inflammation in preterm infants. *Pediatr Pulmonol* **2006**, *41*, 242-249, doi:10.1002/ppul.20350.
65. Young, D.; Lamb, S.E.; Shah, S.; MacKenzie, I.; Tunnicliffe, W.; Lall, R.; Rowan, K.; Cuthbertson, B.H.; Group, O.S. High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med* **2013**, *368*, 806-813, doi:10.1056/NEJMoa1215716.
66. Ismaiel, N.; Whynot, S.; Geldenhuys, L.; Xu, Z.; Slutsky, A.S.; Chappe, V.; Henzler, D. Lung-Protective Ventilation Attenuates Mechanical Injury While Hypercapnia Attenuates Biological Injury in a Rat Model of Ventilator-Associated Lung Injury. *Front Physiol* **2022**, *13*, 814968, doi:10.3389/fphys.2022.814968.
67. Fuchs, H.; Rossmann, N.; Schmid, M.B.; Hoenig, M.; Thome, U.; Mayer, B.; Klotz, D.; Hummler, H.D. Permissive hypercapnia for severe acute respiratory distress syndrome in immunocompromised children: A single center experience. *PLoS One* **2017**, *12*, e0179974, doi:10.1371/journal.pone.0179974.
68. Nin, N.; Muriel, A.; Penuelas, O.; Brochard, L.; Lorente, J.A.; Ferguson, N.D.; Raymondos, K.; Rios, F.; Violi, D.A.; Thille, A.W.; et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. *Intensive Care Med* **2017**, *43*, 200-208, doi:10.1007/s00134-016-4611-1.

69. Yamamoto, R.; Kaito, D.; Homma, K.; Endo, A.; Tagami, T.; Suzuki, M.; Umetani, N.; Yagi, M.; Nashiki, E.; Suhara, T.; et al. Early intubation and decreased in-hospital mortality in patients with coronavirus disease 2019. *Crit Care* **2022**, *26*, 124, doi:10.1186/s13054-022-03995-1.
70. Dupuis, C.; Bouadma, L.; de Montmollin, E.; Goldgran-Toledano, D.; Schwebel, C.; Reignier, J.; Neuville, M.; Ursino, M.; Siami, S.; Ruckly, S.; et al. Association Between Early Invasive Mechanical Ventilation and Day-60 Mortality in Acute Hypoxemic Respiratory Failure Related to Coronavirus Disease-2019 Pneumonia. *Crit Care Explor* **2021**, *3*, e0329, doi:10.1097/CCE.0000000000000329.
71. Shrestha, D.B.; Sedhai, Y.R.; Budhathoki, P.; Adhikari, A.; Pokharel, N.; Dhakal, R.; Kafle, S.; Yadullahi Mir, W.A.; Acharya, R.; Kashiouris, M.G.; et al. Pulmonary barotrauma in COVID-19: A systematic review and meta-analysis. *Ann Med Surg (Lond)* **2022**, *73*, 103221, doi:10.1016/j.amsu.2021.103221.
72. Bajto, P.; Saric, I.; Bugarin, J.D.; Delic, N.; Dosenovic, S.; Ilic, D.; Stipic, S.S.; Duplancic, B.; Saric, L. Barotrauma in patients with severe coronavirus disease 2019-retrospective observational study. *J Thorac Dis* **2023**, *15*, 5297-5306, doi:10.21037/jtd-23-677.
73. Mega, C.; Cavalli, I.; Ranieri, V.M.; Tonetti, T. Protective ventilation in patients with acute respiratory distress syndrome related to COVID-19: always, sometimes or never? *Curr Opin Crit Care* **2022**, *28*, 51-56, doi:10.1097/MCC.0000000000000904.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.